Neurocrine Biosciences Inc (STU:NB3) Stock Price, Trades & News

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Financial Strength

7/10

Name	Current	Vs Industry	Vs History
Cash-To-Debt	3.24
Equity-to-Asset	0.7
Debt-to-Equity	0.12
Debt-to-EBITDA	0.49
Interest Coverage	N/A	N/A	N/A
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	8.83	Distress Grey Safe
Beneish M-Score	-2.3	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	22.8
	3-Year EBITDA Growth Rate	34.5
	3-Year EPS without NRI Growth Rate	22.6
	3-Year FCF Growth Rate	30.8
	3-Year Book Growth Rate	22.5
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	36.01
	Future 3-5Y Total Revenue Growth Rate Estimate	18.65

Momentum Rank

6/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	51.52
	9-Day RSI	59.72
	14-Day RSI	61.92
	3-1 Month Momentum %	28.27
	6-1 Month Momentum %	21.76
	12-1 Month Momentum %	20.64

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.93
	Quick Ratio	2.85
	Cash Ratio	1.58
	Days Inventory	410.45
	Days Sales Outstanding	77.52
	Days Payable	720.22

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-1.2
	Shareholder Yield %	0.01

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	98.17
	Operating Margin %	25.75
	Net Margin %	21.55
	EBITDA Margin %	26.71
	FCF Margin %	26.72
	OCF Margin %	27.76
	ROE %	22.45
	ROA %	15.64
	ROIC %	20.29
	3-Year ROIIC %	16.56
	ROC (Joel Greenblatt) %	94.78
	ROCE %	22.07
	Years of Profitability over Past 10-Year	8
	Moat Score	6
	Tariff Resilience Score	7

GF Value Rank

9/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	26.83
	Forward PE Ratio	23.59
	PE Ratio without NRI	26.95
	Shiller PE Ratio	100.57
	Price-to-Owner-Earnings	26.27
	PEG Ratio	0.65
	PS Ratio	5.77
	PB Ratio	5.14
	Price-to-Tangible-Book	5.14
	Price-to-Free-Cash-Flow	21.61
	Price-to-Operating-Cash-Flow	20.79
	EV-to-EBIT	20.78
	EV-to-Forward-EBIT	16.88
	EV-to-EBITDA	20.03
	EV-to-Forward-EBITDA	17.35
	EV-to-Revenue	5.35
	EV-to-Forward-Revenue	4.48
	EV-to-FCF	19.96
	Price-to-GF-Value	0.92
	Price-to-Projected-FCF	2.03
	Price-to-Median-PS-Value	0.65
	Price-to-Peter-Lynch-Fair-Value	1.08
	Price-to-Graham-Number	2.48
	Price-to-Net-Current-Asset-Value	18.68
	Earnings Yield (Greenblatt) %	4.81
	FCF Yield %	4.75
	Forward Rate of Return (Yacktman) %	22.53

Financials (Next Earnings Date:2026-07-30)

Annual Quarterly TTM

STU:NB3's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Neurocrine Biosciences Inc Executives

Details

GF Value™: €166.59

STU:NB3

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with NB3. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	2,665.756
	EPS (TTM) (€)	5.573
	Beta	0.2298
	3-Year Sharpe Ratio	0.65
	3-Year Sortino Ratio	1.03
	Volatility %	28.38
	14-Day RSI	61.92
	14-Day ATR (€)	4.496782
	20-Day SMA (€)	146.995
	12-1 Month Momentum %	20.64
	52-Week Range (€)	102.45 - 159.8
	Shares Outstanding (Mil)	100.55

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	6
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Neurocrine Biosciences Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Neurocrine Biosciences Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-10-28 16:30	In 107 days
Third quarter earnings results for 2026	2026-10-28 16:00	In 107 days
Second quarter earnings conference call for 2026	2026-07-30 16:30	In 17 days
Second quarter earnings results for 2026	2026-07-30	In 16 days
Guidance call for 2026	2026-06-09 09:20	141.40 (+0.96%)
William Blair 46th Annual Growth Stock Conference	2026-06-02 11:40	138.20 (+2.33%)
General meeting for 2026	2026-05-27 10:30	133.90 (-0.74%)
First quarter earnings conference call for 2026	2026-05-05 16:30	114.35 (+2.74%)
First quarter earnings results for 2026	2026-05-05 16:00	114.35 (+2.74%)
Guidance call for 2026	2026-05-05 11:20	114.35 (+2.74%)

Show

Entries

Neurocrine Biosciences Inc Frequently Asked Questions

What is Neurocrine Biosciences Inc(STU:NB3)'s stock price today?

The current price of STU:NB3 is €153.15. The 52 week high of STU:NB3 is €159.80 and 52 week low is €102.45.

When is next earnings date of Neurocrine Biosciences Inc(STU:NB3)?

The next earnings date of Neurocrine Biosciences Inc(STU:NB3) is 2026-07-30.

Does Neurocrine Biosciences Inc(STU:NB3) pay dividends? If so, how much?

Neurocrine Biosciences Inc(STU:NB3) does not pay dividend.

Press Release

	Subject	Date
	Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results	2026-07-09
	Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia	2026-07-01
	Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Follo	2026-06-15
	Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026	2026-06-15
	Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026	2026-06-15
	Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026	2026-06-15
	Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patient	2026-06-08
	Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Deve	2026-06-08
	Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026	2026-06-03
	Neurocrine Biosciences to Present at Upcoming Investor Conferences in June	2026-05-26

10/Page

Articles on Neurocrine Biosciences Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.